The US Food and Drug Administration (FDA) has introduced a new pilot commissioner’s national priority voucher program aimed at accelerating review times for biotech companies. Announced alongside FDA Commissioner Martin Makary’s keynote at the 2025 Biotechnology Innovation Organization (BIO) International Convention, the program enables qualifying companies to gain FDA review times shortened by one to two months. This initiative is designed to enhance the US biotech industry's competitiveness amid global innovation pressures, particularly from China, and to improve the speed at which critical therapies reach patients.